Clinical trials that use electronic patient-reported outcomes (ePRO) enable patients to respond to surveys and comment on their health status using mobile devices. About a quarter of ongoing clinical trials now incorporate patient-reported findings due to the growing emphasis on a patient-centric approach in study design.

Although ePro tool strategies have been used in clinical research for some time, widespread use has only recently been spurred by a time-sensitive covid-19 pandemic. The possibility of remote access is fueled by the increased availability and adoption of electronic devices and sensors among regulators, physicians, and patients. It will assist in further modernizing clinical trials.

Leveraging Modern Technological Means

Since SARS-CoV-2 and cancer immunotherapy are constantly evolving, it is difficult for researchers to tell whether or not existing vaccinations will be effective against future strains in primary care. In addition to adopting new technology, studies must be modified to account for patients’ social distances and to ensure their safety while still gathering data.

Many other eClinical patient-reported outcome apps have emerged directly from the need for better data visibility and supervision, quicker trial execution, easier real-time data sharing, and enhanced patient comfort and cooperation. By exploiting the ability to obtain their own device information through digital health records quickly, ePRO models and other technologies may help trial managers make solid data-driven choices and avoid risks, making trials more practical, patient-centric, and economical.

ePRO data collection tools may take the form of a universal app that can be utilized with any modern electronic gadget for routine care. The software lets you take images and videos and record audio replies to practice questions. Often, provisioned devices come with preinstalled software. Patients’ adherence may be boosted by tools like reminder alerts, which may be included in the technology.

Primary care providers have built dashboards, visuals, and analyses to facilitate efficient risk management during trials and ensure participant security and data. The potential for losing data points due to electronic patients turning off or modifying their notification settings is mitigated. Sponsors would feel more at ease knowing that sites are monitoring compliance. They can boost results with tools like dashboards that send out phone calls or text messages to remind participants to stay on track.

Validating and Protecting Data

Although these emerging technologies are becoming more useful for streamlining trial data integrity, safety and privacy remain important. Successful clinical practice relies heavily on the work of Clinical Data Management (CDM) teams, who must guarantee the generation of high-quality, thorough clinical data that satisfies regulatory requirements for both safety and effectiveness. Data science tools and technologies are being used in innovative ways to improve verification and reporting, and these methods are revealing significant promise in exposing inaccuracies.

Artificial intelligence (AI) and the creation of visualizations are two of these methods that can significantly improve clinical trial procedures. A truly data-driven approach is fueled by artificial intelligence and machine learning. Sponsors of clinical ink trials can benefit from using these goal-oriented care techniques since they enable the incorporation of past data into future analysis.

Once parameters and other data have been identified through a mobile device, AI can use a rule-based method to detect possible data quality issues, such as repetitive tasks that could be automated throughout the data cleaning process. Artificial intelligence and other data science techniques allow for the automatic detection of potential hotspots for data discrepancies and anomalies. By applying a rule-based approach developed through collaboration with domain experts, these zones can flag potential data abnormalities, speeding up data cleansing.

Limiting the Financial Burden of Trials

Although the total cost of conducting clinical operations can be affected by a wide range of variables, it has been estimated that late-stage clinical studies may account for half or more of the total cost of bringing a medicine to market. The extent of trial sites and pharmacological complexity are two elements that can play a role at the highest levels. Many external factors, including data reconciliation, typical mistakes in data input and reporting, and quality and regulatory measures, can cause delays in a trial’s progress.

ePRO Models

Sponsors and intervention groups would be wise to keep embracing and investing in innovative technologies like these because of the potential savings and increased patient involvement they provide. Although it may have taken a global epidemic to spark innovation in ePRO data collection, the future of patient engagement is bright.

Author
Recent Posts

itdirection

Tech & Sustainable Innovations at IT Direction

Ian McKenzie is a passionate technology writer and advocate for sustainable innovations. With a background in environmental science and tech trends, Ian brings a unique perspective to the intersection of technology and sustainability.